Step by Stepa HemeOncBuddy patient portal

Ramucirumab

Illustration: Ramucirumab

Say it: ram-yoo-SIR-oo-mab · Brand names: Cyramza

Ramucirumab is a targeted antibody medicine that helps cut off the blood supply that tumors need to grow.

What it is

Tumors need new blood vessels to grow. Ramucirumab blocks a receptor called VEGFR2 that blood vessel cells use to answer growth signals. This slows the growth of new blood vessels that feed the tumor.

Often used for

How you get it

You get ramucirumab as an infusion into a vein at a clinic, and each infusion takes about 60 minutes. It is usually given every 2 or 3 weeks, often with chemotherapy or another medicine. Your schedule may be different.

Common side effects and what helps

Call your care team right away if you have

Before you start, tell your team

Good to know

Questions to ask

Side effect guides

Sources

Quick answers

What is Ramucirumab?
Ramucirumab is a targeted antibody medicine that helps cut off the blood supply that tumors need to grow. Brand names: Cyramza.
What is Ramucirumab used for?
stomach cancer; cancer where the esophagus meets the stomach; lung cancer; colon and rectal cancer; liver cancer.
How is Ramucirumab given?
You get ramucirumab as an infusion into a vein at a clinic, and each infusion takes about 60 minutes. It is usually given every 2 or 3 weeks, often with chemotherapy or another medicine. Your schedule may be different.
What are the common side effects of Ramucirumab?
High blood pressure. Diarrhea. Feeling tired. Lower appetite. Headache. Nosebleeds. Swelling in your feet or legs. Protein in your urine.
When should I call my care team while taking Ramucirumab?
Very bad belly pain, swelling, vomiting, or fever (possible sign of a hole in the bowel); Bleeding that will not stop, vomiting blood, or black stools; Chest pain, sudden weakness on one side, or trouble speaking; Severe headache with confusion, seizures, or vision changes; Chills, flushing, or trouble breathing during or after the infusion.

Last updated: 2026-10-27. Medically reviewed by Veli Bakalov, MD, medical oncologist (October 2026). General education from Step by Step, the patient portal of HemeOncBuddy.